Boston Scientific (BSX) EBITDA (2009 - 2026)

Boston Scientific has disclosed EBITDA across 18 years of filings, most recently posting $1.1 billion for Q1 2026.

• EBITDA for Q1 2026 came in at $1.1 billion, up 19.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 billion (up 33.13% YoY), and the FY2025 annual result was $3.6 billion, up 38.8% from the prior year.
• EBITDA came in at $1.1 billion for Q1 2026 at Boston Scientific, up from $825.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.1 billion in Q1 2026 to a low of $358.0 million in Q3 2022.
• The 5-year median for EBITDA is $675.0 million (2024), against an average of $665.2 million.
• Peak annual rise in EBITDA reached 123.33% in 2022, while the deepest fall reached 7.49% in 2022.
• Boston Scientific's EBITDA stood at $402.0 million in 2022, then surged by 45.27% to $584.0 million in 2023, then rose by 15.58% to $675.0 million in 2024, then gained by 22.22% to $825.0 million in 2025, then surged by 33.45% to $1.1 billion in 2026.
• The last three EBITDA figures came in at $1.1 billion (Q1 2026), $825.0 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.